Richard K. Matros
Known title: Chair, CEO and PresidentCIK: 0001184158
Associated companies
Transaction History
| SBRA | ▼ Sell | Open Market | 200,000 | $4.2M | 9/8/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 13,867 | $0 | 8/31/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 14,003 | $0 | 5/29/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 13,358 | $0 | 2/27/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 85,160 | $0 | 2/10/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 223,944 | $4.4M | 1/8/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 319,394 | $0 | 1/8/2026 | View on chart |
| SBRA | ▼ Sell | Gift | 232,936 | $0 | 1/8/2026 | View on chart |
| SBRA | ▼ Sell | Gift | 232,936 | $0 | 1/8/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 99,577 | $0 | 12/31/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 13,141 | $0 | 11/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 13,211 | $0 | 8/29/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 14,197 | $0 | 5/30/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 14,676 | $0 | 2/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 285,144 | $0 | 1/15/2025 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 139,410 | $2.4M | 1/8/2025 | View on chart |
| SBRA | ▼ Sell | Gift | 151,909 | $0 | 1/8/2025 | View on chart |
| SBRA | ▼ Sell | Gift | 151,909 | $0 | 1/8/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 104,716 | $0 | 12/27/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 11,255 | $0 | 11/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 12,159 | $0 | 8/30/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 13,923 | $0 | 5/31/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 14,317 | $0 | 2/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 162,466 | $0 | 1/31/2024 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 66,016 | $900K | 1/5/2024 | View on chart |
| SBRA | ▼ Sell | Gift | 93,042 | $0 | 1/5/2024 | View on chart |
| SBRA | ▼ Sell | Gift | 93,042 | $0 | 1/5/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 117,218 | $0 | 12/28/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 10,907 | $0 | 11/30/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 12,412 | $0 | 8/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 13,455 | $0 | 5/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 12,407 | $0 | 2/28/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 65,737 | $0 | 1/28/2023 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 33,841 | $443K | 1/4/2023 | View on chart |
| SBRA | ▼ Sell | Gift | 66,259 | $0 | 1/4/2023 | View on chart |
| SBRA | ▼ Sell | Gift | 66,259 | $0 | 1/4/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 129,625 | $0 | 12/27/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 9,022 | $0 | 11/30/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 7,628 | $0 | 8/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 7,964 | $0 | 5/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 8,142 | $0 | 2/28/2022 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 106,437 | $1.5M | 1/4/2022 | View on chart |
| SBRA | ▼ Sell | Gift | 218,204 | $0 | 1/4/2022 | View on chart |
| SBRA | ▼ Sell | Gift | 218,204 | $0 | 1/4/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 110,405 | $0 | 12/28/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 13,127 | $0 | 11/30/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 10,410 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sabra Health Care REIT analysts lower price targets
UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.
Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.